<DOC>
	<DOC>NCT02486939</DOC>
	<brief_summary>An Open-label, Safety Extension Study (OLSES) evaluating the longer-term safety and durability of response of subjects who completed 48 weeks of evaluations in the confirmatory safety and efficacy studies, CHS 0214-02 or CHS-0214-04, evaluating CHS-0214 in patients with rheumatoid arthritis (RA) and plaque psoriasis (PsO), respectively.</brief_summary>
	<brief_title>A Long Term Safety Extension Study (CHS-0214-05)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Have completed 48 weeks of evaluations in CHS021402 and, at Week 48, had at least an ACR20, or completed 48 weeks of evaluations in CHS021404 and, at Week 48, had at least a PASI50</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>